Malignant Neoplasms of Respiratory and Intrathoracic Organs clinical trials at UCSF
1 in progress, 1 open to new patients
Trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients With EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)
open to eligible people ages 18 years and up
The goal of this research is to learn if receiving local consolidation therapy (LCT-- surgery, radiation, or a combination of radiation and surgery) after receiving osimertinib can help to control non-small cell lung cancer (NSCLC) compared to continued treatment with osimertinib alone. The safety of this treatment will also be studied. This is an investigational study. Osimertinib is FDA approved and commercially available for the treatment of NSCLC. It is considered investigational to give surgery and/or radiation after osimertinib to patients with NSCLC. Up to 143 participants will be enrolled in this multicenter study. Up to 143 may take part at MD Anderson.
San Francisco, California and other locations